A high-performance program that will give you a significant boost in the practice of your profession"

This Master's Degree offers the student the possibility of updating knowledge using the latest educational technology. It offers a global vision of Pediatric Infectious Diseases, while focusing on the most important and innovative aspects. This program arises as a response to an important need in the field of Infectious Diseases. Today, this need responds, among other things, to the emergence of certain diseases that are unknown or have little practice (zika, chikungunya, hemorrhagic fevers, among others), and with others that have fallen into oblivion or are unknown to less experienced pharmacists such as diphtheria, measles, pertussis (whooping cough), or flaccid paralysis associated with poliovirus vaccines. 

At the therapeutic level, the emergence of resistance (BLEES, MRSA, carbapenem-resistant enterobacteria, etc.), often caused by the unwise and rational use of drugs, creates problems for the clinician when it comes to initial empirical treatment in certain situations. 

On the other hand, parents who refuse vaccines, children from low-income backgrounds, infections in transplant recipients, children with devices, fevers without focus in well-vaccinated children are increasingly common situations that the pharmacist has to deal with.

All this means that, in order to attend to these patients with the maximum guarantee, the pharmacist must continuously keep up to date, even if they are not a specialist, since the percentage of visits or interconsultations related to infection is very high. If we add to this the increasing amount of information provided by parents, sometimes not always contrasted, professional updating becomes essential to be able to provide adequate information according to the current scientific evidence at all times.

With this specialization you will have the opportunity to study a program that brings together the most advanced and in-depth knowledge in the field, where a group of highly regarded professors with extensive international experience provides you with the most complete and up-to-date information on the latest advances and techniques in Pediatric Infectious Diseases.

This Master's Degree in Pediatric Infectious Diseases will help you keep up to date in order to provide complete and quality care"

This Master's Degree in Pediatric Infectious Diseases contains the most complete and up-to-date scientific program on the market. Its most notable features are:

• The development of practical cases presented by experts in Pediatric 
• Infectious Diseases
• The graphic, schematic, and practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
• Latest development in Pediatric Infectious Diseases
• Practical exercises where the self-assessment process can be carried out to improve learning
• A special emphasis on innovative methodologies in Pediatric Infectious Diseases
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Master's Degree is the best investment you can make in the selection of a refresher program for two reasons: in addition to updating your knowledge in Pediatric Infectious Diseases, you will obtain a qualification from TECH Global University"

It includes, in its teaching staff, expert professionals who bring to this program the experience of their work, in addition to recognized specialists from prestigious reference societies and universities.

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive learning experience designed to 
prepare for real-life situations.

The design of this program focuses on Problem-Based Learning, through which the pharmacist must try to solve the different professional practice situations that arise. To do so, the specialist will be assisted by an innovative interactive video system developed by recognized experts in the field of Pediatric Infectious Diseases and with great experience.

Increase your decision-making confidence by updating your knowledge through this Master's Degree"

Take the opportunity to learn about the latest advances in this field and apply it to your daily practice"

A compendium of knowledge created to give pharmacists the opportunity to catch up or incorporate the most advanced knowledge in Pediatric Infectious Diseases on the current scene. With the confidence and solvency of the largest in-Spanish online university in the world. 

A comprehensive teaching program, structured in well-developed teaching units, oriented towards efficient and swift learning that is compatible with your personal and professional life"

Module 1. Current Overview in Infectious Diseases 

1.1. Update on Epidemiological and Public Health Aspects

1.1.1. Current Status of the Epidemiology of Vaccine-Preventable Diseases in the World

1.2. Current Epidemiology of Relevant Infectious Pathologies in our Environment

1.2.1. Current Epidemiology of Bacterial Meningitis
1.2.2. Current Epidemiology of Poliomyelitis and Flaccid Paralysis due to Non-Poliovirus and Live Attenuated Virus Vaccine
1.2.3. Epidemiology of Tuberculosis and its Resistance in High-Income Countries
1.2.4. Epidemiology of Sexually Transmitted Infections in Adolescents

1.3. Transmission Mechanisms in Pediatrics

1.3.1. Dynamics and Transmission Mechanisms of the Most Common Agents in Pediatrics Today (Includes Intrafamily Transmission)
1.3.2. Seasonality of Infection in Pediatrics Outbreak Management

 1.3.2.1. Temporal Epidemiological Parameters in the Most Common Infections in the Community, Common Point Sources, Continuous, Propagative and Mixed exposure

1.4. Microbiota, Defensive and Immunomodulatory Function

1.4.1. Composition of the Intestinal Flora, Modification with Age
1.4.2. Defensive and Immunomodulatory Role of the Microbiota

1.5. Fever and Inflammatory Response

1.5.1. Update on the Role of Fever in Infection and Antipyretic Therapeutics
1.5.2. Inflammatory Response and Systemic Inflammatory Response Syndrome

1.6. Infections in the Immunocompromised Patient

1.7. Image Interpretation of Infectious Diseases in the Pediatric Age

1.7.1. Interpretation of Ultrasound Images Applied to Infectious Pathology
1.7.2. Interpretation of TC Applied to Infectious Pathology
1.7.3. MRI Interpretation Applied to Infectious Pathology

Module 2. The Laboratory in the Diagnosis of Infectious Diseases 

2.1. Sample Collection

2.1.1. Urine culture
2.1.2. Stool Culture
2.1.3. Graham's Test
2.1.4. Blood Cultures
2.1.5. Catheters
2.1.6. Ocular System
2.1.7. Upper Respiratory Tract
2.1.8. Lower Respiratory Tract
2.1.9. Cerebrospinal Fluid
2.1.10. Skin and Soft Tissues
2.1.11. Osteoarticular Infections
2.1.12. Bone Marrow

2.2. Current Application of Rapid Infection Diagnosis Methods in Primary and Specialized Care

2.2.1. Antigen Detection
2.2.2. Direct Sample Staining
2.2.3. Urgent Serology
2.2.4. Molecular Biology Techniques
2.2.5. Accelerating Antimicrobial Susceptibility Testing
2.2.6. Current Proteomic Techniques for the Diagnosis of Infectious Diseases
2.2.7. Shared Microbiologist-Clinician Decisions in Diagnosis and Treatment of Infectious Diseases

2.3. Antibiograms

2.3.1. Interpretation of Antibiograms Practical Guide
2.3.2. Clinical Significance of Bacterial Resistance

2.4. Interpretation of the Microbiological Report of Respiratory Specimens
2.5. Interpretation of the Microbiological Report of Specimens from the Genitourinary Tract and Gastrointestinal Tract
2.6. Interpretation of the Microbiological Blood Culture Report
2.7. Interpretation of Cerebrospinal Fluid Microbiology Report
2.8. Interpretation of the Microbiological Report in Osteoarticular Infection
2.9. Interpretation of the Microbiological Report of Skin and Soft Tissue Samples

Module 3. Infection in the Neonatal Period 

3.1. Neonatal Infection

3.1.1. Current Obstetric Factors Conditioning Neonatal Infection
3.1.2. Causative Agents

3.2. Antibiotherapy in Pregnancy

3.2.1. Current Role of Antibiotherapy During Pregnancy
3.2.2. Current Prophylaxis of Group B Streptococcus Infection

3.3. Emerging Congenital Infections

3.3.1. Chagas Disease
3.3.2. Zika

3.4. Classical Neonatal Infections and Current Epidemiologic Changes

3.4.1. Herpes Virus Infections
3.4.2. Rubella
3.4.3. Cytomegalovirus
3.4.4. The Son of a Mother with Tuberculosis
3.4.5. Update on Necrotizing Enterocolitis

3.5. Vertical Infection

3.5.1. Update on Vertical Infection by Hepatitis B Virus and its Detection

3.6. Neonatal Sepsis

3.6.1. Early Sepsis
3.6.2. Late Onset Sepsis

3.7. Infections in the Neonatal Intensive Care Unit

3.7.1. Current Algorithm of Action for Fever in Children under 30 Days of Age
3.7.2. Neonatal Fungal Infection

3.8. Laboratory Studies in Neonatology Units

3.8.1. Etiological Identification
3.8.2. Inflammatory Markers
3.8.3. Multiorgan Markers

Module 4. Eye, Skin, Soft Tissue and Skeletal System Infections

4.1. Bacterial or Viral Conjunctivitis
4.2. Dacryocystitis
4.3. Endophthalmitis
4.4. Preseptal and Postseptal Orbital Cellulitis
4.5. Bacterial Skin Infections
4.6. Viral Skin Infections
4.7. Parasitic Skin Infections
4.8. Dermatophyte Skin Infections
4.9. Candida and Malasezzia Skin Infections
4.10. Involvement of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Pediatric Skin and Soft Tissue Infections in our Environment
4.11. Adenitis
4.12. Lymphangitis
4.13. Necrotizing Fasciitis
4.14. Bite Infections

4.14.1. Bites in Urban Environment
4.14.2. Bites in Rural Environment

4.15. Osteomyelitis and Arthritis
4.16. Myositis and Pyomyositis
4.17. Spondylodiscitis

Module 5. ENT and Respiratory Infections

5.1. Pharyngotonsillitis

5.2. Peritonsillar Regional Abscesses and Lemierre's Syndrome

5.2.1. Abscesses in Periatonsillar Region
5.2.2. Mastoiditis

5.3. Otitis and Mastoiditis
5.4. Sinusitis
5.5. Update on Diphtheria
5.6. Oral Mucosa Infections Odontogenic Infections
5.7. Common Cold
5.8. Influenza in Pediatrics
5.9. Pertussis Syndrome
5.10. Update on Bronchiolitis Treatment

5.11. Community-Acquired Pneumonia (CAP)

5.11.1. Etiological Agents by Age
5.11.2. Diagnosis
5.11.3. Severity Factors
5.11.4. Treatment

5.12. Pleural Empyema

5.13. Tuberculosis

5.13.1. Current Guidelines
5.13.2. Infections
5.13.3. Disease
5.13.4. Diagnosis
5.13.5. Treatment

Module 6. Gastrointestinal and Urinary Tract Infections and STDs 

6.1. Acute Gastroenteritis

6.1.1. Current Management

6.2. Traveler's Diarrhea in Children
6.3. Current Role of Parasites in Diarrheal Syndromes in our Environment
6.4. Update on Hepatitis A and E

6.5. Hepatitis B y Hepatitis C

6.5.1. Current Treatment Options
6.5.2. Risk Factors for Disease Progression

6.6. Update on Clostridium Difficile in Pediatrics

6.7. Acute Appendicitis in Children

6.7.1. Need or Not of Antibiotic Treatment

6.8. Urinary Infection

6.8.1. Current Treatment Management
6.8.2. Complementary Evaluations
6.8.3. Prophylaxis
6.8.4. Role of Vesicoureteral Reflux

6.9. Epidemiology, Clinical Manifestations, Diagnosis and Treatment of the Most Common Sexually Transmitted Infections

6.9.1. Syphilis
6.9.2. Gonorrhea
6.9.3. Papillomavirus
6.9.4. Chlamydia Trachomatis
6.9.5. Herpes Virus 1 and 2
6.10. Perirectal Abscesses

Module 7. Febrile Syndromes and Exanthems  

7.1. Fever Without a Focus in Children Less than 3 Months Old

7.1.1. Algorithm of Action
7.1.2. Fever of Unknown Origin in Pediatrics

7.2. Recurrent and Periodic Fever

7.2.1. Differential Diagnosis

7.3. Leishmaniasis
7.4. Exanthematous Diseases and Differential Diagnosis
7.5. Mycoplasma Pneumoniae Non-Pulmonary Pathology

Module 8. Nosocomial Infections

8.1. Healthcare Associated Infections (HAIs) in Pediatrics
8.2. Device-Associated Infections

8.2.1. Infections Associated with Intravascular Devices
8.2.2. Ventilator-Associated Infections

8.3. Infection of Surgical Wounds Current Management

Module 9. HIV Infection in Pediatrics and Adolescence 

9.1. Vertical Transmission

9.1.1. Current Situation of Vertical Transmission in our Environment
9.1.2. Prevention and Management

9.2. Infection in Adolescents

9.3. Antiretrovirals in Pediatrics

9.3.1. Updates
9.3.2. Combinations
9.3.3. Determination of Resistance
9.3.4. Side Effects and Metabolic Alterations

9.4. Pharmacokinetics

9.4.1. Interactions
9.4.2. Level Monitoring
9.5. When and How to Start HAART
9.6. Current Management of HBV and HCV Coinfection

Module 10. Systemic, Cardiovascular and Nervous System Infections 

10.1. Myocarditis 

10.2. Bacterial Meningitis

10.2.1. Action in Case of Suspicion

10.3. Viral Meningitis

10.3.1. Current Agents

10.4. Cerebral Abscess

10.4.1. Infections Associated with Surgical Procedures
10.4.2. Venous Thrombosis

10.5. Cat scratch Disease
10.6. Mononucleosis Syndromes

10.7. Hemorrhagic Fevers

10.7.1. Diagnosis
10.7.2. Treatment

10.8. Endocarditis
10.9. Pericarditis
10.10. Encephalitis
10.11. Sepsis, Severe Sepsis and Septic Shock in Pediatrics

Module 11. Infections associated with Social Changes or Deficits 

11.1. Infections associated with Social Deficits

11.1.1. Infections Associated with Social Deficits
11.1.2. Current Child Poverty and Infections in our Environment

11.2. Tropical Diseases

11.2.1. Initial Infection Examination of Newly Arrived Immigrant Children and Children from International Adoptions
11.2.2. Febrile Syndrome in the Child Coming from a Low-Income Country or from the Tropics, Regardless of the Reason for the Trip
11.2.3. Malaria. Current Diagnostic and Therapeutic Management
11.2.4. Vector-Borne Infections Dengue. Chikungunya Zika
11.2.5. Vector-Borne Diseases Schistosomiasis Onchocerciasis
11.2.6. Parasitic Diseases Ascaris, Amoebas, Tenias, Oxyuris, Strongyloides, Trichuris Trichiura

Module 12. Infection in the Patient at Risk 

12.1. Children with Immunomodulatory Treatments in Rheumatology

12.1.1. Management of Patients Undergoing Immunomodulatory Treatments

12.2. Current Empiricism of Infections in Oncology Patients

12.2.1. Adenovirus Infections in Hemato-Oncology
12.2.2. Diagnostic and Therapeutic Approach to Febrile Neutropenia in Cancer Patients
12.2.3. Empirical and Targeted Treatment of Infections in Cancer Patients

12.3. Infections and Current Response to Children with Underlying Pathology

12.3.1. Risk infections in Patients with Hemolytic Anemias (emoglobinopathies and Membranopathies)
12.3.2. Treatment of Severe Neutropenia and Congenital and Functional Asplenia
12.3.3. Infections in Children with Cystic Fibrosis

12.4. Current Approach to Infections in the Transplanted Child

12.4.1. Cytomegalovirus and BK Virus Infections in Transplant Recipients

Module 13. Treatment in Pediatric Infectious Diseases 

13.1. Pharmacokinetics and Pharmacodynamics of Antibacterial Agents in Pediatrics

13.2. Bacterial Resistance and Antibiotherapy

13.2.1. Carbapenem-Resistant Enterobacteriaceae, BLES, MRSA, Vancomycin-Resistant
13.2.2. Resistance to Antifungals

13.3. Choice of Antibiotics in the Different Families

13.3.1. Beta-Lactams
13.3.2. Macrolides
13.3.3. Aminoglycosides
13.3.4. Fluoroquinolones

13.4. Choice Among the Different Families of Antifungals

13.4.1. Azoles
13.4.2. Echinocandins
13.4.3. Polyenes

13.5. Resurrection of Old Therapeutic Agents

13.6. New Antibiotics or Families

13.6.1. Ceftobiprole, Ceftaroline, Doripenem, Dalbavancin, Talavicina, Teixobactin, Ceftolozane-Tazobactam, Ceftazidime-Avibactam, Lugdunin, Oritavancin, Iclaprim, Ramoplanin, Fidaxomicin, Fidaxomicin

13.7. New Tuberculostatics
13.8. Antibiotherapy in Obese Pediatric Patients

13.9. New Requirements for the Rational and Judicious Choice of Suitable Treatment

13.9.1. Antibiotic Policy in Hospitals and Primary Care Optimization Program

13.10. Role of Agriculture and Animal Husbandry in Antibiotic Resistance

13.11. Use of Antivirals

13.11.1. In Immunocompetent Patients
13.11.2. Use of Antivirals in Immunocompromised Patients

13.12. Essential Antiparasitic Drugs in Pediatrics
13.13. Update on Allergy to Anti-Infectives Alternatives
13.14. Monitoring of Anti-Infectives
13.15. Update on the Duration of Antibiotic Treatments

Module 14. Preventive Measures 

14.1. Control and Response to Hospital Outbreaks of Infection

14.1.1. Common Microorganisms
14.1.2. Current Multidrug-Resistant Microorganisms (Including Decontamination in the MRSA Patient)

14.2. Hospital Organization and Control of Today's Multidrug-Resistant Microorganisms
14.3. Current Indications for Isolation in Hospital Pediatrics
14.4. Update on Vaccination of Children in Special Situations
14.5. Current Indications for Antibiotic Prophylaxis
14.6. Indications for Prophylaxis

14.6.1. In case of Accidental Puncture
14.6.2. Indications for Sexual Abuse Prophylaxis

14.7. Post-Exposure Performance

14.7.1. Chickenpox
14.7.2. Measles
14.7.3. In Hepatitis B
14.7.4. In Hepatitis A
14.7.5. Tuberculosis
14.7.6. Tetanus
14.7.7. Rabies

14.8. Current Status of Perioperative Prophylaxis of the Surgical Patient
14.9. Update on Antibiotic Prophylaxis in Transplant Children and Patients Treated for Atypical Hemolytic Uremic Syndrome

Module 15. Public Health Infectious Disease Control and Research 

15.1. Emerging Infectious Diseases
15.2. Diseases in Which Contact Study is Currently Indicated
15.3. Indications of Directly Observed Treatment
15.4. How to Plan a Study in Infectious Diseases?
15.5. Evaluation and Critical Reading of Scientific Publications
15.6. Current Morbidity and Mortality of Pediatric Infectious Diseases
15.7. Seasonality of Infection in Pediatrics

A unique, key, and decisive educational experience to boost your professional development”